Alterity Therapeutics Limited was incorporated under the laws of the Commonwealth of Australia on 11 November 1997. The company is developing first-in-class therapies for the treatment of neurodegenerative diseases. The company's lead drug candidate, ATH 434 (formerly PBT 434), is the first of a new generation of small molecules designed to block the accumulation and aggregation of α-synuclein. Alpha-synuclein, when aggregated in the brain, is a pathological marker of Parkinson's disease and is considered an important biological target for the treatment of these neurodegenerative diseases. 

Alterity Therapeutics (ATHE) shares rose 12.55% in premarket trading after the USPTO granted a new composition of matter patent for its lead drug candidate, ATH434. The patent covers a crystalline form of the mesylate salt and extends intellectual property protection until at least 2045. The company also announced plans to initiate Phase 3 trial activities for Multiple System Atrophy (MSA) by year-end 2026.

Alterity Therapeutics (ATHE) rises 12.55% premarket after USPTO grants new patent for lead drug candidate ATH434

Alterity Therapeutics has received a price target of $12.00 per share from Craig-Hallum. The biotech firm is focused on developing treatments for neurodegenerative diseases. The analyst rating is available on Benzinga's website.

Alterity

Alterity Therapeutics' Price Target Set at $12.00/Share by Craig-Hallum

Alterity Therapeutics announced FDA End-of-Phase 2 meeting minutes confirming a registrational pathway for ATH434 in Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support approval. Phase 3 trial activities are on track to initiate by year-end 2026. The company received a A$3.98 million R&D Tax Incentive refund and strengthened its Board with the appointment of Ann Cunningham. The cash balance as of June 30, 2026 is A$37.3 million.Alterity Therapeutics has announced key developments in its clinical pipeline for ATH434, an investigational treatment for Multiple System Atrophy (MSA). Following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the agency has confirmed a potential registrational pathway for the therapy. The FDA has indicated that <a href="https://www.facebook.com/MSATrust1/posts/encouraging-news-from-the-msa-research-communitya-significant-milestone-has-been/1478391300980584/">a single pivotal Phase 3 trial</a>, supported by existing evidence, could be sufficient to support regulatory approval. This marks a significant milestone in the development of ATH434 and could streamline the approval process for neurological therapies.The Phase 3 trial is expected to focus on functional outcomes relevant to patients, including swallowing difficulties, orthostatic hypotension, and overall disease severity. Enrollment is projected to include approximately 200 participants, with <a href="https://www.facebook.com/MSATrust1/posts/encouraging-news-from-the-msa-research-communitya-significant-milestone-has-been/1478391300980584/">the study running for 12 months</a> and initiating by the end of 2026. In addition to clinical progress, Alterity has received a A$3.98 million R&amp;D Tax Incentive refund and strengthened its Board with the appointment of Ann Cunningham. As of June 30, 2026, the company reported cash reserves of A$37.3 million.

Alterity Therapeutics Receives FDA Approval for MSA Treatment Trial, Q3 Cash Balance at A$37.3mln

Alterity Therapeutics to participate in BTIG Biotechnology Conference 2026, with CEO David Stamler hosting 1-on-1 meetings with investors. The company is developing disease-modifying treatments for neurodegenerative diseases, with a focus on Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, and its lead asset ATH434 has demonstrated clinically meaningful efficacy in a randomized Phase 2 clinical trial. The company is based in Melbourne, Australia, and San Francisco, California.Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) is set to participate in the BTIG Biotechnology Conference 2026, with CEO David Stamler scheduled to <a href="https://kalkinemedia.com/au/news/announcements/alterity-therapeutics-ceo-to-speak-at-virtual-btig-biotechnology-conference-2026-on-july-28-29">host one-on-one meetings with investors</a>. The company, which operates from Melbourne, Australia, and San Francisco, California, is focused on developing <a href="https://alteritytx.com/events-and-presentations">disease-modifying therapies for neurodegenerative conditions</a>, particularly Multiple System Atrophy (MSA) and related Parkinsonian disorders.The company’s lead candidate, ATH434, has <a href="https://alteritytx.com/events-and-presentations">demonstrated clinically meaningful efficacy</a> in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with MSA. The drug has received both Fast Track and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), reflecting the <a href="https://www.manilatimes.net/2026/06/09/tmt-newswire/globenewswire/alterity-therapeutics-achieves-alignment-with-us-fda-on-pivotal-phase-3-program-for-ath434-in-multiple-system-atrophy/2361541">significant unmet medical need for MSA</a>, a rare and rapidly progressive neurodegenerative disease with no approved therapy.Following a successful End-of-Phase 2 meeting with the FDA, Alterity has achieved alignment on the key elements of its proposed Phase 3 trial design, including <a href="https://www.manilatimes.net/2026/06/09/tmt-newswire/globenewswire/alterity-therapeutics-achieves-alignment-with-us-fda-on-pivotal-phase-3-program-for-ath434-in-multiple-system-atrophy/2361541">study population, dosing regimen, and primary endpoint</a>. The FDA agreed to the use of the 11-item UMSARS Part I as the primary endpoint, based on ATH434’s 48% slowing of disease progression compared to placebo in the Phase 2 study. The Phase 3 trial is <a href="https://www.manilatimes.net/2026/06/09/tmt-newswire/globenewswire/alterity-therapeutics-achieves-alignment-with-us-fda-on-pivotal-phase-3-program-for-ath434-in-multiple-system-atrophy/2361541">expected to initiate by year-end 2026</a>.The upcoming conference participation provides an opportunity for Alterity to engage with investors and further communicate its strategic progress in advancing ATH434 toward potential regulatory approval.

Alterity Therapeutics to Present at BTIG Biotechnology Conference 2026

Alterity Therapeutics plans to initiate a Phase 3 trial of ATH434 in Multiple System Atrophy (MSA) after receiving FDA meeting minutes confirming a potential trial design, including a study population, treatment regimen, and efficacy endpoints. The trial is expected to enroll 200 patients and will be randomized to receive ATH434 or placebo twice daily for 12 months. The FDA has also agreed on key secondary endpoints and the Unified Multiple System Atrophy Rating Scale Part I as the primary endpoint.Alterity Therapeutics has announced plans to initiate a Phase 3 clinical trial of ATH434 for the treatment of Multiple System Atrophy (MSA) following alignment with the U.S. Food and Drug Administration (FDA) on key trial design elements. The pivotal trial will enroll approximately 200 patients with MSA and will be randomized, double-blind, and placebo-controlled, with participants receiving ATH434 50 mg twice daily or matching placebo for 12 months. The FDA has agreed to use the 11-item Unified Multiple System Atrophy Rating Scale Part I (UMSARS I) as the primary endpoint, reflecting <a href="https://www.biospace.com/press-releases/alterity-therapeutics-achieves-alignment-with-u-s-fda-on-pivotal-phase-3-program-for-ath434-in-multiple-system-atrophy">48% slowing of functional decline</a> observed in the Phase 2 trial. Key secondary endpoints include the <a href="https://www.biospace.com/press-releases/alterity-therapeutics-achieves-alignment-with-u-s-fda-on-pivotal-phase-3-program-for-ath434-in-multiple-system-atrophy">Swallowing Disturbance Questionnaire, Orthostatic Hypotension</a> Symptom Assessment, and the Clinical Global Impression of Severity.The Phase 3 trial will incorporate biomarker and imaging data from earlier studies, including quantitative susceptibility mapping, which showed <a href="https://www.clinicaltrialvanguard.com/news/alteritys-ath434-shows-48-slowing-of-decline-in-msa-phase-2-trial/">reduced iron accumulation in brain</a> regions affected by MSA. The FDA also concurred with Alterity’s <a href="https://www.biospace.com/press-releases/alterity-therapeutics-achieves-alignment-with-u-s-fda-on-pivotal-phase-3-program-for-ath434-in-multiple-system-atrophy">proposed statistical methods and safety</a> database size. The trial is expected to begin by year-end 2026, with results potentially supporting <a href="https://www.biospace.com/press-releases/alterity-therapeutics-achieves-alignment-with-u-s-fda-on-pivotal-phase-3-program-for-ath434-in-multiple-system-atrophy">a New Drug Application for ATH434</a> in MSA, a disease with no approved therapies.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1cca25632034d001.png" alt="Alterity to Initiate Phase 3 Trial of ATH434 in MSA Following FDA's EOP2 Minutes.">

ATHE News